Genetics, Ancestry, and Hypertension: Implications for Targeted Antihypertensive Therapies
- 421 Downloads
Hypertension is the most common chronic condition seen by physicians in ambulatory care and a condition for which life-long medications are commonly prescribed. There is evidence for genetic factors influencing blood pressure variation in populations and response to medications. This review summarizes recent genetic discoveries that surround blood pressure, hypertension, and antihypertensive drug response from genome-wide association studies, while highlighting ancestry-specific findings and any potential implication for drug therapy targets. Genome-wide association studies have identified several novel loci for inter-individual variation of blood pressure and hypertension risk in the general population. Evidence from pharmacogenetic studies suggests that genes influence the blood pressure response to antihypertensive drugs, although results are somewhat inconsistent across studies. There is still much work that remains to be done to identify genes both for efficacy and adverse events of antihypertensive medications.
KeywordsGenetics Hypertension Genome-wide association studies Ancestry Pharmacogenetics
NIH U01- GM074492 (to RKCD)
Compliance with Ethics Guidelines
Conflict of Interest
Nora Franceschini and Daniel I. Chasman declare that they have no conflicts of interest.
Rhonda M. Cooper-DeHoff has received research grants from NIH and Abbott Laboratories. She also has received a patent for clinical trial software and royalties from the University of Florida Foundation.
Donna K. Arnett has received a grant from the NIH.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 7.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). Shep Cooperative Research group. JAMA. 1991;265:3255–64.Google Scholar
- 8.Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension detection and follow-up program cooperative group. JAMA. 1979;242:2562–71.Google Scholar
- 9.Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–52.Google Scholar
- 10.Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (syst-eur) Trial Investigators. Lancet. 1997;350:757–64.PubMedCrossRefGoogle Scholar
- 11.MRC trial of treatment of mild hypertension: principal results. Medical research council working party. Br Med J (Clin Res Ed). 1985;291:97–104.Google Scholar
- 12.Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens. 1985;3:379–92.Google Scholar
- 16.•Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9. This is the largest GWAS of BP published. It identified 29 SNPs in 28 loci for BP traits and hypertension. The study comprised of 69,395 individuals of European ancestry for discovery and approximately 200,000 individuals were included in the discovery and replication samples.Google Scholar
- 19.Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009.Google Scholar
- 20.Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009.Google Scholar
- 22.Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, et al. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial no synthase. Hypertension. 2012;59:248–55.PubMedCentralPubMedCrossRefGoogle Scholar
- 28.•Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat Genet. 2011;43:531–8. A large GWAS of East Asians. It identified four new loci (ST7L-CAPZA1, FIGN-GRB14, ENPEP and NPR3) and a newly discovered variant near TBX3. The paper compares the effect estimates for the ICBP SNPs between European and East Asian studies.PubMedCentralPubMedCrossRefGoogle Scholar
- 30.Zhu X, Young JH, Fox E, Keating BJ, Franceschini N, Kang S, et al. Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet. 2011;20(11):2285–95.Google Scholar
- 31.•Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. Am J Hum Genet. 2013;93:545–54. This is the largest GWAS of BP in African ancestry individuals. The study identified three novel loci for blood pressure traits and allelic heterogeneity in one known locus.PubMedCentralPubMedCrossRefGoogle Scholar
- 46.Staessen JA, Kuznetsova T, Roels HA, Emelianov D, Fagard R. Exposure to cadmium and conventional and ambulatory blood pressures in a prospective population study. Public Health and Environmental Exposure to Cadmium Study Group. Am J Hypertens. 2000;13(2):146–156.Google Scholar
- 47.Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect. 2008;116(1):51–56.Google Scholar
- 59.•Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013;62:391–7. Two recent GWAS of blood response to antihypertensive drugs.PubMedCentralPubMedCrossRefGoogle Scholar
- 62.•Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012;5:686–91. Two recent GWAS of blood response to antihypertensive drugs.PubMedCentralPubMedCrossRefGoogle Scholar
- 66.McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) Study. PLoS ONE 2013;8(10): e76984. doi: 10.1371/journal.pone.0076984
- 67.Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23:470–8.Google Scholar
- 68.Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genomics. 2013;23:697–705.Google Scholar
- 69.James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA. 2014;311:507–20.PubMedCrossRefGoogle Scholar
- 70.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). JAMA. 2002;288:2981–97.Google Scholar
- 73.Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014.Google Scholar